Caris Life director gets stock in lieu of cash
POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director George Poste reported routine equity compensation and a prior ownership reclassification. He received 1,600 shares of common stock as a grant in lieu of cash 2026 board retainer fees, based on a ten-day average price of $15.62 per share. After this award, he holds 17,729 shares directly. A previous transfer of 204,108 shares from direct ownership into a family trust contributed to an indirect total of 511,702 shares, and did not change his overall beneficial ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 1,600 shares
Grant/Award
2 txns
Insider
POSTE GEORGE
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,600 | $15.62 | $25K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 17,729 shares (Direct);
Common Stock — 511,702 shares (Indirect, By Family Trust)
Footnotes (2)
- F1. Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.
- F2. Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities.
Key Figures
Stock grant: 1,600 shares
Reference price: $15.62 per share
Direct holdings after grant: 17,729 shares
+2 more
5 metrics
Stock grant
1,600 shares
Common stock issued in lieu of 2026 board cash retainer
Reference price
$15.62 per share
Ten-day average volume-weighted average price through May 29, 2026
Direct holdings after grant
17,729 shares
Common stock directly owned after the 1,600-share award
Indirect holdings via family trust
511,702 shares
Common stock held indirectly through a family trust
Shares transferred to trust
204,108 shares
Previously moved from direct ownership to a family trust
Key Terms
in lieu of cash compensation, volume weighted average price, beneficial ownership, family trust
4 terms
in lieu of cash compensation financial
"Shares issued in lieu of cash compensation for 2026 board retainer fees."
volume weighted average price financial
"ten trading day average of the daily volume weighted average price per share"
The volume weighted average price (VWAP) is a way to measure the average price of a security, such as a stock, over a specific period, taking into account how many units were traded at each price. It’s similar to calculating the average cost of items bought when some are more frequently purchased than others. Investors use VWAP to assess whether a security is being bought or sold at a fair price during trading.
beneficial ownership financial
"The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
family trust financial
"transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Caris Life Sciences (CAI) report for George Poste?
Caris Life Sciences reported a routine equity grant to director George Poste. He received 1,600 common shares as compensation, rather than cash, for his 2026 board retainer fees, and his overall beneficial ownership remained unchanged after a prior transfer to a family trust.
What price was used to calculate George Poste’s Caris Life Sciences (CAI) stock grant?
The stock grant was based on a reference price of $15.62 per share. The company determined the 1,600-share award by dividing the cash retainer earned by the ten trading day average volume-weighted average price per share through May 29, 2026.
What are George Poste’s direct and indirect Caris Life Sciences (CAI) holdings after this filing?
After the reported transactions, George Poste directly holds 17,729 shares. He also indirectly holds 511,702 shares through a family trust, reflecting a prior transfer of 204,108 shares that did not change his aggregate beneficial ownership of Caris Life Sciences stock.
Did the family trust transfer change George Poste’s total Caris Life Sciences (CAI) ownership?
No, the transfer to the family trust did not change his total beneficial ownership. A prior movement of 204,108 shares from direct ownership into a family trust only shifted how the shares are held, with the position now reflected as indirect ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
